Immune Response BioPharma, Inc.

Immune Response BioPharma, Inc. Sets Pricing of REMUNE Vaccine in Thailand Between $75-100 Per Dose for Emergency Approval of HIV/AIDS Vaccine

Immune Response BioPharma, Inc. to Seek Emergency Approval of REMUNE in Thailand & Begin Stockpiling HIV/AIDS Vaccine

Immune Response BioPharma, Inc. to Seek Orphan Designation of NeuroVax for Pediatric Multiple Sclerosis to Expand Use of Novel Vaccine Treatment. Immune Response BioPharma, Inc.

Immune Response BioPharma, Inc. Selects the American Stock Transfer & Trust Company as Transfer Agent of Record.

Immune Response BioPharma, Inc. Posts 2nd Half 2012 & Full Year Results

Immune Response BioPharma, Inc. Files for Orphan Designation of REMUNE for Pediatric HIV/AIDS

Immune Response BioPharma, Inc. Announces New ZORCELL Psoriasis Vaccine Phase IIb Study Safety & Efficacy 350 Patients ZORCELL + Methotrexate 6 Months Study.

Immune Response BioPharma, Inc. Adopts Shareholder Rights Plan & Poison Pill Anti-Takeover Provision

Immune Response BioPharma, Inc. to Develop Zorcell Psoriasis Vaccine the First Vaccine for Psoriasis & Reviews Phase II Results

Immune Response BioPharma, Inc. Publishes Phase III Full 806 Study Results, REMUNE Very Effective Demonstrating 0.7% HIV Progression vs 6% Estimated Rate & Subgroup Median Virologic Failure Delayed by 20 Weeks In REMUNE Group.